Please assess the completion status of the following clinical trial:

Trial Title: Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Infant or child aged 1 month to 17 years, who meets clinical criteria for KD according to American Heart Association guidelines (Table 2): Fever (T≥38oC or 100.4oC) ≥ 3 days and ≥ 2 clinical criteria with left anterior descending (LAD)/right coronary artery (RCA) Z score ≥ 3.0 or an aneurysm (≥ 1.5 x the adjacent segment) of one of the coronary artery segments~2. Patient presents within the first 20 days after fever onset~3. Parent or legal guardian able and willing to provide informed consent; adolescent or child assent as appropriate~4. Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of contraception during the study~5. Males engaging in sexual activity that could lead to pregnancy willing to use a condom.~Exclusion Criteria:~1. Use of an IL-1 antagonist within the 3 months prior to enrollment~2. History of chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder~3. History of hypersensitivity to anakinra~4. History of tuberculosis (TB) or TB exposure

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).